Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Approves Symbicort Asthma Combo Therapy

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approved AstraZeneca's asthma therapy Symbicort (budesonide/formoterol) July 21 for patients 12 and older after a standard 10-month review

You may also be interested in...



AstraZeneca Wants COPD Label For Symbicort

Newly reported trials prove safety and efficacy, company says.

AstraZeneca Wants COPD Label For Symbicort

Newly reported trials prove safety and efficacy, company says.

AstraZeneca Will Acquire Verus Asthma Program In Deal Worth $310 Million

Agreement will allow AstraZeneca to continue building its pediatric respiratory franchise, firm tells "The Pink Sheet" DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel